Krystal Biotech
KRYS Nasdaq· Biotechnology
Last close · Oct 23, 2026
$311.50
KIRA · Stoqly’s AI analyst, in plain words
- Krystal Biotech had $389M of revenue in fiscal 2025, up 33.9% on the year before.
- Its operating margin was 41.5%, up 18.8 pts: of every 100 in sales, about 41 is left after running the business.
- Krystal Biotech made $205M of net profit in fiscal 2025.
- Free cash flow was $189M in fiscal 2025, 48.6% of revenue.
- Krystal Biotech returned $0.0M to shareholders in fiscal 2025, 0% of free cash flow. The diluted share count rose 0.7%.
- Krystal Biotech has $828M more cash than debt.
Market cap
$9.6B
P/E
39.0x
Revenue
$389M
Net income
$205M
Free cash flow
$189M
Operating margin
41.5%
Krystal Biotech in 30 seconds · fiscal 2025
Are sales growing?
+33.9%
Yes. Sales grew 33.9% last year.
Does it make a profit?
52.6%
Yes. It keeps 52.6% of every sale as profit.
Does profit turn into cash?
48.6%
Yes. 48.6% of sales ends up as free cash.
Is debt under control?
Net cash
Yes. It has more cash than debt.
How healthy are the accounts?
5 / 8
Mixed. It passes 5 of 8 health tests.
How is the share priced?
39.0x
One share costs 39.0 times its yearly profit per share. Typical for its sector: 27.9x.
What Krystal Biotech does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 17, 2026
- Legal name
- Krystal Biotech, Inc.
- CIK
- 0001711279
Krystal Biotech · KRYS
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.0M | $0.0M | $50.7M | $291M | $389M |
| Revenue growth | — | — | — | 473.0% | 33.9% |
| Operating margin | — | — | −216.2% | 22.6% | 41.5% |
| Net income | −$69.6M | −$140M | $10.9M | $89.2M | $205M |
| Net margin | — | — | 21.6% | 30.7% | 52.6% |
| Diluted EPS | −$3.13 | −$5.49 | $0.39 | $3.00 | $6.84 |
| Cash | |||||
| Cash from operations | −$47.9M | −$101M | −$88.8M | $123M | $201M |
| Capital expenditure | $68.3M | $53.0M | $11.8M | $4.2M | $12.0M |
| Free cash flow | −$116M | −$154M | −$101M | $119M | $189M |
| FCF margin | — | — | −198.4% | 41.0% | 48.6% |
| Dividends paid | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Share buybacks | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Share count change | 18.2% | 14.9% | 8.9% | 7.2% | 0.7% |
| Debt and strength | |||||
| Cash and short-term investments | $438M | $379M | $532M | $598M | $828M |
| Debt incl. finance leases | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | $594M | $522M | $779M | $946M | $1.2B |
| Net debt / EBITDA | — | — | — | −8.3x | −5.0x |
| Current ratio | 17.2x | 13.3x | 17.8x | 7.3x | 10.0x |
| Interest coverage | −45.8x | — | — | — | — |
| Returns and quality | |||||
| Return on capital | −61.2% | −76.9% | −47.7% | 20.7% | 43.6% |
| Return on equity | −15.7% | −25.1% | 1.7% | 10.3% | 18.9% |
| Piotroski F-score | — | 2 | 4 | 5 | 5 |
| Altman Z'' | 22.0 | 15.9 | 23.1 | 12.9 | 16.6 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$105M
6 insiders
Of sales under plans
87%
$92.1M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Krystal Biotech · KRYS
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Similar companies
Each company’s latest fiscal year. Fiscal years end in different months, so periods don’t line up exactly.
| Company | Market cap | Growth | Op. margin | FCF margin | ROIC | P/E | F-score |
|---|---|---|---|---|---|---|---|
| Krystal Biotech KRYS | $9.6B | 33.9% | 41.5% | 48.6% | 43.6% | 39.0x | 5 |
| ADMA Biologics ADMA | $2.5B | 19.6% | 37.5% | 5.5% | 39.5% | 15.3x | 5 |
| Ligand Pharmaceuticals LGND | $6.6B | 60.4% | 15.3% | 18.2% | 4.9% | 32.3x | 5 |
| Repligen RGEN | — | 16.4% | 7.5% | 12.7% | 2.4% | — | — |
| Arrowhead Pharmaceuticals ARWR | $8.3B | 23,258.2% | 11.9% | 18.9% | — | — | 5 |
Price compared with profit (P/E)
How many times its yearly profit per share one share costs. Higher means investors pay more for each unit of profit.
KIRA
At $311.50 a share, the company is worth $9.6B: 39.0 times its earnings of the last four quarters.
Krystal Biotech grew sales faster than 2 of its 4 similar companies. Its P/E is higher than 2 of 2.
Source: SEC EDGAR XBRL filings (CIK 0001711279). Data updated October 16, 2026. For information only — not investment advice. Check the original filings before relying on any figure.